Hypothalamic-pituitary Dysfunction in Diabetes
Key facts
- Who runs it
- Istituto Auxologico Italiano
- Where
- Italy2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 200 people enrolled
- Started
- 25 May 2018
- Ended
- 14 Mar 2024
- Type of study
- Observational
- Treatments tested
- Diagnostic testing
- Record updated
- 15 March 2024
Who can take part
- Age
- 18 years to 80 years
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- age between 18 and 80 years old
- males
- proved diagnosis of T2DM
Who cannot take part
- patients affected with known hypothalamic-pituitary diseases at the enrollment
- patients affected with known primary diseases of the testes at the enrollment
- patients affected with severe systemic diseases, fever, chronic inflammatory disorders with PCR > 10 mg/dL
- malnutrition with BMI <17 Kg/m2
- use of glucocorticoids at the enrollment
- poor understanding of spoken and written Italian
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Type 2 Diabetes mellitus (T2DM) is a chronic disease with a high prevalence and several comorbidities impacting on public health and society. Among the complications of T2DM it has been showed a high prevalence of hypogonadotropic hypogonadism. Even if hypogonadism is associated to a worse metabolic profile and cardiovascular risk, it is discussed whether and when to treat this potentially reversible form associated to diabetes. In fact, the pathogenic mechanism of this condition in diabetic patients is not fully understood, and its clinical correlates, including the prevalence of other possible associated hypothalamic-pituitary axes dysfunctioning, questioned. The aim of the present study is to assess with an observational, cross sectional study on a large series of type 2 diabetic patients, enrolled consecutively: all the suspected etiologies of this complication in one single evaluation (both acquired and genetic congenital predisposition), its clinical correlates and the real prevalence of the disease using the lastly validated criteria for late onset hypogonadotropic hypogonadism.
The group in the trial
- Enrolled patients with DM
Treatment: Diagnostic testing
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Study of the Hypothalamic-pituitary Dysfuntion in Patients With Diabetes Mellitus
- Record updated
- 15 March 2024